
Harbor Health Care ETF (MEDI)
Built on a rich history of Health Care Investing
Locate Your Harbor Consultant
INSTITUTIONAL INVESTORS ONLY: Please enter your zip code to locate an Investment Consultant.
Welcome
Why Invest in MEDI?
Health care costs have increased over time, while forecasts signal continued upward trend looking ahead. A broader shift towards value-based approaches within health care is likely needed, with emphasis on lower costs of care and improved patient outcomes. This enables opportunities for health care companies best positioned to facilitate transition towards value over quantity.
In addition, health care is home to other disruptive themes such as targeted oncology, liquid biopsy, gene therapy, orphan diseases, and others that represent compelling long-term growth opportunities.
The investment team behind MEDI seeks to construct a portfolio capable of benefiting from the secular growth and innovation of the U.S. health care system, while achieving alpha relative to the broader Health Care sector by investing in quality businesses with differentiated products, technologies, and services which meet the team's disciplined valuation criteria.

Matthew R. Renna "Health care is a sector that we are very passionate about, and one in which we have a strong history." |
Time to get active in healthcare investing
"Health care is a sector that we are very passionate about, and one in which we have a strong history."
Matthew R. Renna
Partner, Portfolio Manager, Westfield Capital Management Company L.P.
Performance
Distribution History
Ex-Date
Record Date
Payable Date
Ordinary Income
Short Term Capital Gains
Long Term Capital Gains
Total Distribution
12/21/2022
12/22/2022
12/27/2022
--
--
--
0.00000
Holdings
Full Holdings
As of 9/21/2023
Company Name [Ticker]
Category Name
Country
Cusip
Shares
Current Price ($)
Market Value ($)
% of Net Assets
ELI LILLY & CO [LLY]
EQUITY
532457108
1,120
550.13
616,145.60
13.9
UNITEDHEALTH GROUP INC [UNH]
EQUITY
91324P102
991
501.14
496,629.74
11.2
ASCENDIS PHARMA A/S - ADR [ASND]
EQUITY
04351P101
4,877
95.44
465,460.88
10.5
HUMANA INC [HUM]
EQUITY
444859102
482
494.06
238,136.92
5.4
DEXCOM INC [DXCM]
EQUITY
252131107
2,335
89.08
208,001.80
4.7
ROCKET PHARMACEUTICALS INC [RCKT]
EQUITY
77313F106
9,905
20.84
206,420.20
4.7
LEGEND BIOTECH CORP-ADR [LEGN]
EQUITY
52490G102
2,724
63.54
173,082.96
3.9
INTUITIVE SURGICAL INC [ISRG]
EQUITY
46120E602
578
284.35
164,354.30
3.7
ICON PLC [ICLR]
EQUITY
G4705A100
640
251.87
161,196.80
3.6
MERCK & CO. INC. [MRK]
EQUITY
58933Y105
1,401
106.73
149,528.73
3.4
OPTION CARE HEALTH INC [OPCH]
EQUITY
68404L201
3,807
33.06
125,859.42
2.8
GE HEALTHCARE TECHNOLOGY [GEHC]
EQUITY
36266G107
1,869
63.89
119,410.41
2.7
THERMO FISHER SCIENTIFIC INC [TMO]
EQUITY
883556102
216
501.59
108,343.44
2.5
ALKERMES PLC [ALKS]
EQUITY
G01767105
3,346
29.71
99,409.66
2.2
SAREPTA THERAPEUTICS INC [SRPT]
EQUITY
803607100
677
119.55
80,935.35
1.8
COOPER COS INC/THE [COO]
EQUITY
216648402
238
328.39
78,156.82
1.8
CENCORA INC [COR]
EQUITY
03073E105
389
184.93
71,937.77
1.6
ALIGN TECHNOLOGY INC [ALGN]
EQUITY
016255101
239
300.28
71,766.92
1.6
INSPIRE MEDICAL SYSTEMS INC [INSP]
EQUITY
457730109
363
191.21
69,409.23
1.6
BIO-TECHNE CORP [TECH]
EQUITY
09073M104
957
69.92
66,913.44
1.5
IDEXX LABORATORIES INC [IDXX]
EQUITY
45168D104
151
438.65
66,236.15
1.5
AVANTOR INC [AVTR]
EQUITY
05352A100
2,893
21.57
62,402.01
1.4
VAXCYTE INC [PCVX]
EQUITY
92243G108
1,101
52.19
57,461.19
1.3
NEUROCRINE BIOSCIENCES INC [NBIX]
EQUITY
64125C109
502
113.11
56,781.22
1.3
LANTHEUS HOLDINGS INC [LNTH]
EQUITY
516544103
926
60.27
55,810.02
1.3
VERADIGM INC [MDRX]
EQUITY
01988P108
4,221
12.57
53,057.97
1.2
HAEMONETICS CORP/MASS [HAE]
EQUITY
405024100
527
90.09
47,477.43
1.1
MOONLAKE IMMUNOTHERAPEUTICS [MLTX]
EQUITY
61559X104
867
53.18
46,107.06
1.0
INNOVIVA INC [INVA]
EQUITY
45781M101
3,469
12.93
44,854.17
1.0
MASIMO CORP [MASI]
EQUITY
574795100
387
97.03
37,550.61
0.8
BIO-RAD LABORATORIES-A [BIO]
EQUITY
090572207
94
357.30
33,586.20
0.8
89BIO INC [ETNB]
EQUITY
282559103
1,542
15.64
24,116.88
0.5
REPLIGEN CORP [RGEN]
EQUITY
759916109
133
161.72
21,508.76
0.5
CEREVEL THERAPEUTICS HOLDING [CERE]
EQUITY
15678U128
1,033
20.63
21,310.79
0.5
CRISPR THERAPEUTICS AG [CRSP]
EQUITY
H17182108
200
46.06
9,212.00
0.2
Total
--
--
--
--
--
4,409
99.5
Cash and Other Assets Less Liabilities
--
--
--
--
--
--
0.5
Total Net Assets
--
--
--
--
--
--
100%
Sector Allocation
As of 8/31/2023
Health Care ETF (MEDI)
Russell 3000 Growth Health Care Index
Health Care
MEDI: 98.4%
Benchmark: 100.0%
Consumer Discretionary
MEDI: 0.0%
Benchmark: 0.0%
Consumer Staples
MEDI: 0.0%
Benchmark: NaN%
Industrials
MEDI: 0.0%
Benchmark: 0.0%
Materials
MEDI: 0.0%
Benchmark: 0.0%
MEDI: Health Care ETF
Benchmark: Russell 3000 Growth Health Care Index
Sector Returns
As of 8/31/2023
Economic Sector
Health Care ETF %
Russell 3000 Growth Health Care Index %
Health Care
5.2
6.0
Industrials
0.0
-14.5
Information Technology
0.0
-17.0
Consumer Discretionary
0.0
9.1
Materials
0.0
48.1
Consumer Staples
0.0
129.2
Investment Team

Westfield Capital Management Company, L.P. is dedicated to providing strong and consistent investment performance based on a disciplined, team-based approach, with exceptional client service. Westfield believes their greatest strength comes from the collective wisdom of a fully engaged and inspired team working together with clear objectives. Additionally, Westfield embraces their partnership structure, which aligns the advancement of the organization with their clients and serves to attract and retain exceptional talent.
Documents
Investing involves risk, principal loss is possible. Unlike mutual funds, ETFs may trade at a premium or discount to their net asset value. Harbor ETFs are new and have limited operating history to judge.
Shares are bought and sold at market price not net asset value (NAV). Market price returns are based upon the closing composite market price and do not represent the returns you would receive if you traded shares at other times.
There is no guarantee that the investment objective of the Fund will be achieved. Stock markets are volatile and equity values can decline significantly in response to adverse issuer, political, regulatory, market and economic conditions. Since the Fund may hold foreign securities, it may be subject to greater risks than funds invested only in the U.S. These risks are more severe for securities of issuers in emerging market regions. Foreign currencies can decline in value and can adversely affect the dollar value of the fund. Since the Fund typically invests in a limited number of companies, an adverse event affecting a particular company may hurt the Fund's performance more than if it had invested in a larger number of companies. Health Care Industry Risk: Because the Fund seeks to invest all, or substantially all, of its assets in the health care industry, the value of its shares will depend on the general condition of the that industry. The health care industry may be affected by any number of factors, including, but not limited to, lapsing patent protection, industry innovation, extensive government regulation, restrictions on government reimbursement for medical expenses, research and development costs, limited product lines, product liability litigation, an increased emphasis on outpatient services, and competitive forces. Authorized Participant Concentration/Trading Risk: Only authorized participants ("APs") may engage in creation or redemption transactions directly with the Fund. The Fund is classified as non-diversified, a non-diversified Fund may invest a greater percentage of its assets in securities of a single issuer, and/or invest in a relatively small number of issuers, it is more susceptible to risks associated with a single economic, political or regulatory occurrence than a more diversified portfolio. New Fund Risk: There can be no assurance that the Fund will grow to or maintain an economically viable size, in which case the Board of Trustees may determine to liquidate the Fund. Small and Mid Cap Risk: The Fund's performance may be more volatile because it may invest in issuers that are smaller companies.
The views expressed herein may not be reflective of current opinions, are subject to change without prior notice, and should not be considered investment advice.
Weighted Average Market Capitalization: The average size of the companies in a portfolio or index as measured by the market value of outstanding shares.
Price/Book: The price-to-book (P/B) ratio evaluates a firm's market value relative to its book value.
Adjusted Trailing P/E Ratio: The Adjusted Trailing P/E (Price/Earnings) Ratio is the closing stock price divided by the sum of the last 12 months actual EPS.
% EPS Growth – Past 3 year: Earnings per share refers to the bottom-line measure of a company’s profitability defined as net income divided by the number of outstanding shares.
Return on Equity: Return on equity (ROE) is a measure of financial performance calculated by dividing net income by shareholders' equity.
Forecasted P/E Ratio: a measure of the P/E (price-to-earnings) ratio using forecasted earnings for the P/E calculation.
Bid/Ask Mid Price: the midpoint between the highest bid and the lowest offer, as of the time that the Fund’s NAV is calculated, typically 4 p.m. Eastern Time.
Premium/Discount ($): the difference between the Fund’s market price and NAV, expressed as a percentage of NAV. A premium is the amount that the Fund is trading above the reported NAV. A discount is the amount that the Fund is trading below the reported NAV.
30-Day Median Bid/Ask Spread: calculated by identifying national best bid and national best offer ("NBBO") for each fund as of the end of each 10 second interval during each trading day of the last 30 calendar days and dividing the difference between each such bid and offer by the midpoint of the NBBO. The median of those values is identified and that value is expressed as a percentage (rounded to the nearest hundredth).
2912371